Loading…
Shenzhen-based pharma company focused on cardiovascular and metabolic drugs, expanding into innovative biologics.
Shenzhen-based pharma company focused on cardiovascular and metabolic drugs, expanding into innovative biologics.
Sells mainly cardiovascular prescription drugs to hospitals; its original mainstay, the anti-clot drug clopidogrel, lost ground when China's state volume-based purchasing rounds forced generic prices down. It has since leaned on newer heart-failure and blood-pressure drugs and is investing in biologic medicines still in development.
Moat: narrow (brand, regulatory licence). Established cardiovascular drug franchise and regulatory approvals built over two decades.
Headquarters: Shenzhen, China · Employees: 4,087
Size Shenzhen Salubris Pharmaceuticals (002294.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $5.18B, the 486th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥31.21 on 6 Nov 2026.
Performance Over six months the shares fell 39.1%, against +2.5% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 19 in its peer set.
Growth Revenue grew 14.2% over the last twelve months (peer median +10.6%); the operating margin is 11.3% (peer median 20.6%).
Valuation It trades at 41.6× forward earnings against a peer median of 31.2× (3rd most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.85B | CN¥4.31B | CN¥3.98B | CN¥3.34B | CN¥3.45B |
| Revenue growth | — | +8% | +19% | -3% | — |
| Gross profit | CN¥3.86B | CN¥3.13B | CN¥2.81B | CN¥2.21B | CN¥2.37B |
| EBITDA | n/a | CN¥1.07B | CN¥1.08B | CN¥927M | CN¥922M |
| Net income | CN¥715M | CN¥652M | CN¥602M | CN¥580M | CN¥637M |
| Free cash flow | CN¥200M | CN¥144M | CN¥607M | CN¥199M | CN¥379M |
| Capital expenditure | CN¥1.00B | CN¥974M | CN¥625M | CN¥671M | CN¥599M |
| Total debt | CN¥966M | CN¥711M | CN¥134M | CN¥63.5M | CN¥614M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals 002294.SZ | $5.18B | -39% | +14% | 11% | 41.6× | 15.5% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
| Livzon Pharmaceutical 000513.SZ | $3.71B | -4% | -14% | 19% | 16.9× | -9.8% |
| Cspc Pharma 1093.HK | $12.4B | +5% | +25% | 28% | 9.3× | -10.3% |
| Huadong Medicine 000963.SZ | $7.29B | -17% | +2% | 9% | 14.0× | -2.7% |
| Sbp 1177.HK | $12.7B | +4% | +15% | 30% | 18.3× | -5.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002294.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.5% | +2.0% | 10th highest of 20 |
| 6-month return | -39.1% | +2.5% | 2nd lowest of 19 |
| Distance from 52-week high | -56.0% | -27.4% | 2nd lowest of 21 |
| Revenue growth (TTM) | +14.2% | +10.6% | 8th highest of 19 |
| Operating margin | 11.3% | 20.6% | 6th lowest of 19 |
| Forward P/E | 41.6× | 31.2× | 3rd most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 15.5% | 8.0% | 6th most demanding of 18 |
| Growth delivered (Del g) | +9.7% | +12.2% | 8th lowest of 18 |
| Hurdle (Req g minus delivered) | +5.8 pp | -3.4 pp | 4th most demanding of 18 |
| ROIC minus cost of capital | +2.9 pp | +4.7 pp | 8th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $5.18B | -39% | +14% | 11% | 41.6× | 15.5% | +9.7% |
| IPCA Laboratories IPCALAB.NS | India | $5.22B | +24% | +11% | 17% | 32.4× | 17.8% | +12.2% |
| Sumitomo Pharma 4506.T | Japan | $5.23B | +7% | +11% | 10% | 8.3× | 1.4% | -2.6% |
| SKBP 326030.KS | South Korea | $5.12B | -11% | +39% | 35% | 21.6× | 0.5% | +93.6% |
| Beijing TongRenTang 600085.SS | China | $5.27B | -8% | -17% | 8% | 31.2× | 2.7% | +6.2% |
| Erasca ERAS | United States | $5.04B | +42% | n/a | n/a | n/a | n/a | n/a |
| Supernus Pharmaceuticals SUPN | United States | $5.43B | -49% | +16% | 45% | 6.7× | 4.2% | +13.9% |
| PTC Therapeutics PTCT | United States | $5.47B | -11% | -35% | 22% | 34.8× | 8.0% | +35.4% |
| Gland Pharma GLAND.NS | India | $5.53B | +69% | +18% | 20% | 39.0× | 28.0% | +13.3% |
| Novast Laboratories 301569.SZ | China | $4.82B | n/a | +3% | 27% | n/a | 42.6% | +3.1% |
| Apotex Health APTX.TO | Canada | $5.62B | n/a | +4% | 32% | 18.6× | -13.5% | +4.2% |
| Travere Therapeutics TVTX | United States | $4.76B | +16% | +49% | -3% | 16.9× | 16.7% | +19.9% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% | +3.0% |
| Veradermics MANE | United States | $5.80B | +31% | n/a | n/a | n/a | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | China | $4.61B | -11% | +1% | 3% | 13.3× | -0.3% | +4.7% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.90B | -6% | +39% | 47% | 13.8× | 1.8% | +519.6% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $4.53B | -17% | +60% | -4% | 64.5× | n/a | n/a |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.53B | +2% | +12% | 33% | 35.9× | 25.2% | +5.5% |
| Abbott India ABBOTINDIA.NS | India | $5.93B | -1% | +6% | 28% | 32.4× | 11.4% | +10.0% |
| Camurus CAMX.ST | Sweden | $4.52B | +47% | 0% | 37% | 48.5× | 10.4% | +46.5% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 33.9× | 14.9% | +12.7% |